How Long Does It Take to Get Methotrexate Out of Your System?

Methotrexate leaves the bloodstream relatively quickly, with a plasma half-life of roughly 3 to 10 hours for standard low doses and somewhat longer for the high doses used in cancer treatment. Most people will have cleared the drug from their blood within a day or two of a typical weekly dose. But “out of your system” is more complicated than blood levels alone suggest, because methotrexate gets trapped inside cells in a modified form that can persist for weeks or longer, and that intracellular reservoir is what makes the drug work as well as it does for conditions like rheumatoid arthritis.

How the Kidneys Handle Methotrexate

The kidneys do the heavy lifting. At high doses, roughly 90% of methotrexate is excreted unchanged through the kidneys, involving a combination of filtration and active tubular secretion.¹ At the lower doses typically used for autoimmune conditions and psoriasis, the kidneys still handle the majority of elimination, though the proportion drops to around 65% of total clearance, with the liver and other pathways picking up the remainder.² This distinction matters because how well your kidneys work essentially determines how fast the drug leaves your blood.

Because methotrexate clearance is so kidney-dependent, even mild kidney impairment can slow things down. The drug accumulates in the body when the kidneys cannot keep pace, and that accumulation raises the risk of side effects like mouth sores, liver damage, and drops in blood cell counts.³ In clinical settings where patients receive high-dose methotrexate for cancer, doctors routinely check kidney function before each cycle and monitor blood levels of the drug afterward for exactly this reason.

The Drug That Lingers Inside Your Cells

Blood levels tell only part of the story. Once methotrexate enters a cell, enzymes tack extra glutamate molecules onto it, creating what are called polyglutamates.⁴ These modified forms cannot easily slip back out through the cell membrane, so they become trapped. Research on cultured cells has shown that polyglutamate formation allows prolonged retention of the drug and continued suppression of cell activity long after the drug has disappeared from the fluid outside the cell.⁵

This intracellular stockpile is actually the therapeutic engine behind low-dose methotrexate for rheumatoid arthritis and similar conditions. Patients take the drug only once a week, and blood levels drop to near zero within a day or two, but the polyglutamates inside immune cells keep working throughout the week. Red blood cells, which are easy to sample, serve as a convenient window into how much methotrexate your body is holding onto at the cellular level. Measuring polyglutamate concentrations in red blood cells can help gauge whether a given dose is producing the intended effect.⁶ Various factors influence these levels, including how long a patient has been on the drug and the weekly dose.⁷

So when people ask how long methotrexate stays in their system, the honest answer has two parts. The drug itself clears from the blood in hours to a couple of days. The intracellular polyglutamate forms take considerably longer to break down and wash out, which is why doctors talk about washout periods measured in weeks or months rather than days.

Third-Space Fluid Traps

A less obvious reason clearance can stall has nothing to do with the kidneys or cells. If you have a buildup of fluid somewhere it does not normally collect, such as fluid around the lungs (a pleural effusion) or fluid in the abdomen (ascites), methotrexate can soak into that fluid reservoir and slowly leak back into the bloodstream over time. This extends the drug’s plasma half-life and can dramatically increase the risk of toxicity.⁸

Modeling of this phenomenon has shown that for a drug like methotrexate, which naturally distributes into a relatively small volume in the body, a large effusion can increase the terminal half-life by several hundred percent.⁹ Even unusual fluid collections like large liver cysts can trap the drug. In one reported case, a patient with Burkitt lymphoma and large liver cysts experienced severely delayed methotrexate clearance despite normal kidney and liver function, because the drug accumulated in the cysts and was slowly released back into circulation.¹⁰ When high-dose methotrexate is planned, clinicians typically drain any accessible fluid collections beforehand to avoid this problem.

Urine pH Makes a Measurable Difference

Methotrexate becomes less soluble in acidic urine, which can cause it to crystallize in the kidney tubules and damage the kidneys. This is why patients receiving high-dose methotrexate are given intravenous fluids and sodium bicarbonate to keep their urine alkaline.¹¹ But alkalinizing the urine does more than prevent crystal formation. It actually speeds up how fast the kidneys clear the drug.

An early pharmacokinetic study found that the ratio of methotrexate clearance to creatinine clearance climbed steadily as urine became more alkaline, roughly tripling as pH rose from 5.5 to 8.4.¹² Interestingly, simply drinking more water (increasing urine flow) did not have as strong an independent effect on clearance as pH did. The practical implication for patients on high-dose regimens is that keeping urine alkaline is not just a safety precaution against kidney damage but a strategy for getting the drug out of the body faster. A systematic review confirmed that urine alkalinization prevents kidney toxicity in patients receiving high-dose methotrexate.¹³

Genetic Variation in Clearance Speed

Not everyone clears methotrexate at the same rate, even with identical kidney function. A genome-wide association study in children with acute lymphoblastic leukemia identified a gene called SLCO1B1 as a significant player in how quickly the body eliminates the drug. Variants in this gene accounted for about 11% of the population-level variability in methotrexate clearance, and patients carrying certain rare damaging variants had notably slower clearance than others.¹⁴

A systematic review looking at genetic influences on high-dose methotrexate clearance in pediatric leukemia patients confirmed that SLCO1B1 has the most consistent impact but also flagged several other genes involved in drug transport and metabolism.¹⁵ This research is still being translated into clinical practice, but the direction is toward eventually using a patient’s genetic profile to predict whether they are a fast or slow clearer and adjust dosing or monitoring accordingly.

Does Age Slow Clearance?

This is one of those questions where the evidence is muddier than you might expect. In one study of patients with primary central nervous system lymphoma, delayed methotrexate clearance was observed in about 11% of patients over 60 compared with 3% of those 60 or younger, though the difference did not reach conventional statistical significance with the sample sizes involved.¹⁶ That trend makes biological sense because kidney function tends to decline with age, and methotrexate elimination is so kidney-dependent.

However, a prospective pharmacokinetic study in adult lymphoma patients found that age, sex, weight, and liver function did not independently impact methotrexate clearance after accounting for kidney function.¹⁷ The takeaway is that age probably matters, but mainly because older kidneys tend to work less efficiently. If an older patient has well-preserved kidney function, their methotrexate clearance may be perfectly fine. The kidney itself is the rate-limiting step, not the birthday.

Emergency Removal When Clearance Fails

When high-dose methotrexate does not clear on schedule, the situation can become dangerous quickly. The standard first-line rescue is folinic acid (also called leucovorin), which is given intravenously to protect healthy cells from methotrexate’s toxic effects. The dose and duration are guided by blood methotrexate levels and how the patient is doing clinically.¹⁸ Folinic acid does not remove methotrexate from the body; it outcompetes the drug inside cells, essentially blunting its damage. Whether the rescue starts early enough and at a high enough dose turns out to matter quite a bit for preventing complications like nerve damage.¹⁹

When blood levels remain dangerously high despite leucovorin and kidney support, the drug glucarpidase (also known by its former name carboxypeptidase G2) offers a more direct solution. It is an enzyme that chews methotrexate into inactive fragments right in the bloodstream. Studies have shown it produces more than an 87% reduction in blood methotrexate concentrations and is well tolerated.²⁰ It works fast enough that it is considered more effective than any dialysis method for acute removal.

Dialysis can pull methotrexate out of the blood, but its usefulness has limits. A systematic review from the EXTRIP workgroup, which evaluates extracorporeal treatments for poisoning, found methotrexate to be only moderately dialyzable by standard hemodialysis. The group actually recommended against using dialysis when glucarpidase is available, partly because dialysis mainly clears what is in the bloodstream while methotrexate rapidly distributes into cells, and partly because dialysis also removes the protective leucovorin.²¹ That said, when glucarpidase is unavailable or delayed, newer combinations of high-flux hemodialysis with hemoadsorption cartridges have shown promising results. In one case, a combined session reduced methotrexate levels by over 90%, with an estimated elimination half-life of less than an hour during treatment.²² These scenarios apply to high-dose oncology settings, not to the weekly low-dose tablets most people with autoimmune conditions take.

How Long to Wait Before Trying to Conceive

Methotrexate is known to cause birth defects and pregnancy loss, so a washout period after stopping the drug is standard medical advice for anyone planning a pregnancy. The specifics of how long to wait, however, vary depending on who you ask. Clinical guidelines generally recommend waiting at least three months after the last dose, while the drug’s manufacturer advises six months.²³

The three-to-six-month range is not based on how long the drug stays in the blood, which is a matter of days. It is based on the intracellular polyglutamate forms that linger much longer, the time it takes for any affected eggs or sperm to cycle through, and a general margin of safety. The discrepancy between the three-month and six-month recommendations has been a source of anxiety for patients, particularly those who conceive sooner than planned after methotrexate treatment for an ectopic pregnancy or other condition. If you are in this situation, the conversation with your doctor should focus on your specific dosing history and timing, not on a single blanket number.

Surgery and Methotrexate

For years, the conventional approach was to stop methotrexate a couple of weeks before and after surgery, based on worry that a drug affecting immune cells would increase infection risk or slow wound healing. An older review noted that some rheumatologists and surgeons considered withholding the drug for about two weeks around surgery to be reasonable.²⁴

More recent evidence has largely reversed this thinking. Multiple studies, including a large randomized trial of nearly 400 patients, found that continuing methotrexate through surgery was not associated with increased infection or wound-healing problems. In fact, the randomized trial found a perioperative infection rate of only 2% in the group that kept taking methotrexate, compared with 15% in those who stopped it, likely because disease flares from interrupting treatment created their own problems. A multidisciplinary expert consensus now recommends continuing methotrexate perioperatively, including on the day of surgery.²⁵ This is a case where the old instinct to “clear the drug first” turned out to do more harm than good.

Methotrexate in Breast Milk

Since methotrexate is a potent drug, the question of whether it passes into breast milk matters for nursing mothers who need it. A case report measuring methotrexate and its metabolite in breast milk after a high dose found that levels were very low and fell to near-minimum concentrations within about 24 hours. The relative infant dose was estimated at 0.11%, which is extremely small.²⁶ That number sounds reassuring, but the researchers still urged caution given the drug’s inherent toxicity, particularly its effects on rapidly dividing cells like those found in an infant’s gut lining and bone marrow. Most guidelines recommend against breastfeeding while on methotrexate, or at least pumping and discarding milk for a period after each dose. The data are limited enough that this remains a risk-benefit discussion rather than a settled policy.

Why Plasma Monitoring Does Not Tell the Whole Story

If you are on low-dose methotrexate for an autoimmune condition and your doctor draws a blood sample to check drug levels, the plasma concentration may not reflect much about how the drug is actually working. Because the active polyglutamate forms accumulate inside cells rather than floating free in the blood, plasma-based monitoring does not capture the drug’s true therapeutic footprint. Researchers have developed methods to measure polyglutamate concentrations directly in red blood cells, and these intracellular measurements are a more reliable window into how much drug your body is holding onto and whether your dose is in the effective range.⁶ This kind of testing is not yet routine in most clinics, but it is an area of active development and may eventually give patients and doctors a clearer picture of when methotrexate has truly left the system at the cellular level.